TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18215618
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (substrates of ABCB1)
Study: 16377916
Drug: Nasal nocturnal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nasal nocturnal oxygen therapy (HOT group, n=25)
Study: 14651540
Drug: Tolmetin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin (25 mg/kg per day)
Study: 14651540
Drug: Aspirin (75-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (75-100 mg/kg per day)
Study: 8972376
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation during surgery
Study: 8972376
Drug: Air inhalation
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air inhalation during surgery
Study: 1592575
Drug: Selegiline (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (a selective MAO-B inhibitor)
Study: 6375274
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg/ml
Study: 6375274
Drug: Nicomorphine 10
Normalized name: apomorphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicomorphine 10 mg/ml
Study: 6375274
Drug: Pethidine 75
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 75 mg/ml
Study: 30664050
Drug: Active transcranial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcranial direct current stimulation with methadone maintenance treatment
Study: 30664050
Drug: Sham transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transcranial direct current stimulation with methadone maintenance treatment
Study: 30664050
Drug: Only methadone
Normalized name: Product containing only methadone (medicinal product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only methadone maintenance treatment
Study: 22340283
Drug: AZD9773 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9773 (50 or 250 units/kg single doses; multiple doses of 250 units/kg loading and 50 units/kg maintenance, 500 units/kg loading and 100 units/kg maintenance, or 750 units/kg loading and 250 units/kg maintenance)
Study: 19877169
Drug: Rosiglitazone (RSG),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (RSG), 8 mg/day for 2 years
Study: 19877169
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) for 2 additional years after initial treatment
Study: 12105140
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/d)
Study: 10420109
Drug: Tobramycin 0.3%
Normalized name: TOBRAMYCIN 0.3% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3% eye drops 4 times daily
Study: 1341875
Drug: Captopril associated
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril associated with conventional treatment (digitalis and diuretic)
Study: 1341875
Drug: Captopril associated
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril associated with digitalis or diuretic
Study: 1341875
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (digitalis and diuretic)
Study: 6659641
Drug: Penbutolol (negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (negative inotropic agent)
Study: 6659641
Drug: AR‐L 115
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR‐L 115 BS (positive inotropic drug)
Study: 30924348
Drug: Application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antineutrophil cytoplasm autoantibody testing and the European Medicines Agency algorithm
Study: 29378016
Drug: ASP9226 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP9226 (30 mg)
Study: 29378016
Drug: ASP9226 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP9226 (50 mg)
Study: 24520664
Drug: L-carnitine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine + tadalafil
Study: 24520664
Drug: Safety of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety of medication
Study: 22847195
Drug: Vitamins (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins (1000 mg of vitamin C, 800 IU of vitamin E, and 300 mg of Coenzyme Q‐10) for 14 days
Study: 12151908
Drug: Donepezil (DPZ)
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil (DPZ) 10 mg/day
Study: 8665881
Drug: Neostigmine (0.036
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.036 mg kg‐1)
Study: 30586695
Drug: Patisiran (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran (0.3 mg/kg via intravenous infusion once every 3 weeks for 18 months)
Study: 26825829
Drug: Paclitaxel (PTX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (PTX, 175 mg/m²) plus Carboplatin (CBDCA) (TC chemotherapy)
Study: 26825829
Drug: Docetaxel (DTX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (DTX, 60 mg/m²) plus Carboplatin (CBDCA) (DC chemotherapy)
Study: 26825829
Drug: Both TC
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TC and DC chemotherapy
Study: 25902653
Drug: Meldonium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meldonium (1 g/day intravenously for 2 weeks then orally until 1.5 months)
Study: 22087585
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day free plant sterols and stanols
Study: 17367312
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks
Study: 17367312
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks
Study: 17367312
Drug: Rosuvastatin and
Normalized name: rosuvastatin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and Atorvastatin
Study: 7922450
Drug: Growth factors
Normalized name: INVEST HEMATOLOGIC DEFICIENCIES,HEMATOPOEITIC GROWTH FACTORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth factors in combination with specialized nutrition
Study: 3149548
Drug: Adenosine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (various doses, intra-arterial)
Study: 26576946
Drug: Blended Motivational
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended Motivational Interviewing and Problem Solving Therapy (MI-PST)
Study: 21039351
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at target effect-site concentrations of 2.0, 2.5, 3.0, 3.5, and 4.0 microg/ml during TCI with sufentanil (0.2 ng/ml)
Study: 17133564
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 to 3 g/day with reduced CNI dose (≥50% of initial dose)
Study: 17133564
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MMF, CNI dose not reduced below 75% of initial dose)
Study: 1279468
Drug: Ranitidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (50 mg 4 times a day e.v.)
Study: 1279468
Drug: No anti
Normalized name: Cellano antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti H2 treatment (Control)
Study: 3769898
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg meptazinol i.m.
Study: 26482543
Drug: Doxepin hydrochloride
Normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin hydrochloride (6 mg) in tomato juice
Study: 22200728
Drug: Bosentan, 125
Normalized name: Bosentan, 125 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan, 125 mg two times per day, n = 28
Study: 18568482
Drug: Axitinib (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib (administered orally twice daily until disease progression or intolerance)
Study: 15752950
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d of oral folic acid for 4 weeks
Study: 10342484
Drug: Therapeutic massage
Normalized name: All Body Powerful Therapeutic Massager
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic massage sessions of 10 minutes per day in combination with treatment with pressure garments
Study: 8595539
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray, 2 sprays/nostril bid
Study: 8595539
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray, 2 sprays/nostril qd
Study: 8595539
Drug: Oral chlorpheniramine
Normalized name: chlorpheniramine Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chlorpheniramine maleate, 12 mg bid
Study: 1790542
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg thrice daily)
Study: 6111632
Drug: Propranolol (60‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (60‐120 mg/day)
Study: 28453849
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) with initial efavirenz
Study: 25784719
Drug: CDP7657 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP7657 IV (0.004-5 mg/kg)
Study: 25784719
Drug: CDP7657 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP7657 IV (5-60 mg/kg)
Study: 12501898
Drug: Misoprostol (1-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (1-11 tablets, vaginal route)
Study: 9831367
Drug: IFN-alpha +
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha + Talpha1 (1 mg twice weekly)
Study: 7716590
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg every 8 hours
Study: 7716590
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg every 6 hours
Study: 788079
Drug: Intravenous plasminogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plasminogen
Study: 30884961
Drug: Telephone-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive behavioral therapy (CBT)
Study: 21666588
Drug: Cytoflavin, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin, 2 ml/kg/day, intravenously for 5 days
Study: 21666588
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment without cytoflavin
Study: 19299322
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba 120 mg twice daily for 12 days
Study: 19299322
Drug: Voriconazole 200
Normalized name: voriconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole 200 mg alone
Study: 11565630
Drug: Pagoclone 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pagoclone 0.1 mg t.d.s.
Study: 9137213
Drug: Amiodarone, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone, 300 mg/day
Study: 9137213
Drug: Nonantiarrhythmic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonantiarrhythmic therapy
Study: 30818782
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day iron (800 mg of iron protein succinylate)
Study: 27864718
Drug: 32 NaP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 NaP tablets
Study: 27864718
Drug: 4 L
Normalized name: PEG-4 laurate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 L of PEG
Study: 23727761
Drug: Dance/movement therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance/movement therapy
Study: 11015108
Drug: Bladder-drainage with
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder-drainage with induction immunotherapy
Study: 11015108
Drug: Enteric-drainage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-drainage with induction immunotherapy
Study: 11015108
Drug: Enteric-drainage without
Normalized name: ENTERAL DRAINAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-drainage without induction immunotherapy
Study: 26997110
Drug: Phone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phone administration preference
Study: 22443183
Drug: Insulin dose
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose increase (≥ 10% at week 12 and ≥ 10% at week 24)
Study: 20139217
Drug: Delayed use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed use of antibiotics
Study: 20139217
Drug: Antibiotic delay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic delay strategy
Study: 11333850
Drug: Beta-carotene dissolved
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene dissolved in oil (80 microg per capsule) consumed 2 capsules/day, 7 days/week for up to 10 weeks
Study: 2894890
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 to 40 mg once daily
Study: 24284249
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 20/40 mg administered via intravenous injection after admission with 12 hours intervals for six times
Study: 24284249
Drug: Morphine 2/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2/4 mg initially, additional morphine 2 mg as needed
Study: 10924972
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation (AF) of 30 Gy in 10 daily fractions
Study: 10924972
Drug: Accelerated hyperfractionated
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionated (AH) radiotherapy (1.6 Gy b.i.d. to a total dose of 54.4 Gy)
Study: 1423948
Drug: 12,500 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12,500 IU heparin s.c.
Study: 24154666
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment (up to 200 mg/d over 10 weeks)
Study: 18211496
Drug: Topical antimycotic
Normalized name: ANTIMYCOTICS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimycotic treatment
Study: 16983120
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of induction therapy with HAM (high-dose cytarabine and mitoxantrone)
Study: 16983120
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction therapy without HAM
Study: 11020031
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg/day
Study: 11020031
Drug: propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol 80 mg/day
Study: 1569652
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg ascorbic acid (placebo)
Study: 1569652
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ascorbic acid
Study: 11198264
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg ascorbic acid
Study: 1569652
Drug: 2,000 mg
Normalized name: garlic 2,000 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 mg ascorbic acid
Study: 2857181
Drug: SPH (PAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPH (PAS plus isoniazid daily for 18 months with streptomycin for the first three months)
Study: 2857181
Drug: PH (PAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: PH (PAS plus isoniazid daily for 18 months without streptomycin)
Study: 2857181
Drug: IP (inpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP (inpatient rest in bed for six months followed by outpatient treatment)
Study: 2857181
Drug: OP (ambulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: OP (ambulatory outpatient treatment from the start)
Study: 2857181
Drug: J (outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: J (outpatient treatment with a plaster-of-Paris jacket for nine months)
Study: 2857181
Drug: No J
Normalized name: Alfamino Junior Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: No J (ambulatory treatment without any support)
Study: 2857181
Drug: Additional chemotherapy
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional chemotherapy and/or operation
Study: 2857181
Drug: Additional chemotherapy
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional chemotherapy and/or surgery
Study: 29704010
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (IP) after NACT and IDS
Study: 29704010
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (IV) after NACT and IDS
Study: 29704010
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (IP) after PDS
Study: 29704010
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (IV) after PDS
Study: 24817084
Drug: Non-laxative preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-laxative preparation
Study: 22745235
Drug: HAM‐RS2 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAM‐RS2 (40 g/d)
Study: 18478213
Drug: NGF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGF (5 microg in 0.2 ml) injection into the masseter muscle
Study: 18478213
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.9%, 0.2 ml) injection into the masseter muscle
Study: 18478213
Drug: Glutamate (1
Normalized name: Glutamate (13-N)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamate (1 M, 0.2 ml) injection after 24 h
Study: 10369259
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with ALOX5-pathway modifiers
Study: 2203282
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg epinephrine (LE)
Study: 2203282
Drug: 0.4 ml
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 ml saline (L)
Study: 9272316
Drug: Tobramycin ophthalmic
Normalized name: tobramycin ophthalmic
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin ophthalmic solution
Study: 19809809
Drug: Fenugreek seed
Normalized name: FENUGREEK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek seed extract (588 mg)
Study: 19809809
Drug: Fenugreek seed
Normalized name: FENUGREEK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek seed extract (1176 mg)
Study: 17578980
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral controlled-release oxycodone every 12 hours from the evening before surgery until the second postoperative morning.
Study: 17578980
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral controlled-release oxycodone
Study: 16353064
Drug: Isosorbide-5-mononitrate (ephox-long,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (ephox-long, 50-100 mg o.d.)
Study: 16353064
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (nitrosorbide, 10-20 mg t.i.d.)
Study: 10468697
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. during dosing
Study: 10468697
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.d. before dosing
Study: 2079386
Drug: viloxazine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: viloxazine (400 mg per os daily)
Study: 6998538
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin prophylaxis (5000 i.u. every 12 h for 5‐7 days) + graduated compression stockings
Study: 25283480
Drug: Higher-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose vitamin D3 (2000 IU/800 IU)
Study: 25283480
Drug: Lower-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose vitamin D3 (1000 IU/400 IU)
Study: 19573122
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (QW)
Study: 6140220
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg i.v.)
Study: 2908765
Drug: Clonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3 mg p.o.)
Study: 30107819
Drug: Structured, non-pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured, non-pharmacological care delivered by students of medicine, psychology and nursing, together with standard medical treatment
Study: 25644495
Drug: Septal body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septal body volume reduction (SBVR) with concurrent bilateral microdebrider-assisted SBVR during turbinate surgery
Study: 22282887
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus insertion of a lumbar drain
Study: 18065789
Drug: Antimicrobial lock
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial lock solution (ALS)
Study: 16107989
Drug: DMAS device
Normalized name: DLin-MC3-DMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMAS device with monthly adherence counseling
Study: 320671
Drug: Ibuprofen, 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 1,800 mg/day
Study: 320671
Drug: Aspirin, 3,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 3,600 mg/day
Study: 31995406
Drug: Standardized antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized antihypertensive treatment (triple therapy)